CONTEXT: The long-term effects of pure 17β-estradiol (E₂) depending on route of administration have not been well characterized. OBJECTIVE: Our objective was to assess metabolic effects of oral vs transdermal (TD) 17β-E₂ replacement using estrogen concentration-based dosing in girls with Turner syndrome (TS). PATIENTS: Forty girls with TS, mean age 16.7 ± 1.7 years, were recruited. DESIGN: Subjects were randomized to 17β-E₂ orally or TD. Doses were titrated using mean E₂ concentrations of normally menstruating girls as therapeutic target. E₂, estrone (E₁), and E₁ sulfate (E₁S) were measured by liquid chromatography tandem mass spectrometry and a recombinant cell bioassay; metabolites were measured, and dual-energy x-ray absorptiometry scan and indirect calorimetry were performed. MAIN OUTCOME: Changes in body composition and lipid oxidation were evaluated. RESULTS: E₂ concentrations were titrated to normal range in both groups; mean oral dose was 2 mg, and TD dose was 0.1 mg. After 6 and 12 months, fat-free mass and percent fat mass, bone mineral density accrual, lipid oxidation, and resting energy expenditure rates were similar between groups. IGF-1 concentrations were lower on oral 17β-E₂, but suppression of gonadotropins was comparable with no significant changes in lipids, glucose, osteocalcin, or highly sensitive C-reactive protein between groups. However, E₁, E₁S, SHBG, and bioestrogen concentrations were significantly higher in the oral group. CONCLUSIONS: When E₂ concentrations are titrated to the normal range, the route of delivery of 17β-E₂ does not affect differentially body composition, lipid oxidation, and lipid concentrations in hypogonadal girls with TS. However, total estrogen exposure (E₁, E₁S, and total bioestrogen) is significantly higher after oral 17β-E₂. TD 17β-E₂ results in a more physiological estrogen milieu than oral 17β-E₂ administration in girls with TS.
RCT Entities:
CONTEXT: The long-term effects of pure 17β-estradiol (E₂) depending on route of administration have not been well characterized. OBJECTIVE: Our objective was to assess metabolic effects of oral vs transdermal (TD) 17β-E₂ replacement using estrogen concentration-based dosing in girls with Turner syndrome (TS). PATIENTS: Forty girls with TS, mean age 16.7 ± 1.7 years, were recruited. DESIGN: Subjects were randomized to 17β-E₂ orally or TD. Doses were titrated using mean E₂ concentrations of normally menstruating girls as therapeutic target. E₂, estrone (E₁), and E₁ sulfate (E₁S) were measured by liquid chromatography tandem mass spectrometry and a recombinant cell bioassay; metabolites were measured, and dual-energy x-ray absorptiometry scan and indirect calorimetry were performed. MAIN OUTCOME: Changes in body composition and lipid oxidation were evaluated. RESULTS: E₂ concentrations were titrated to normal range in both groups; mean oral dose was 2 mg, and TD dose was 0.1 mg. After 6 and 12 months, fat-free mass and percent fat mass, bone mineral density accrual, lipid oxidation, and resting energy expenditure rates were similar between groups. IGF-1 concentrations were lower on oral 17β-E₂, but suppression of gonadotropins was comparable with no significant changes in lipids, glucose, osteocalcin, or highly sensitive C-reactive protein between groups. However, E₁, E₁S, SHBG, and bioestrogen concentrations were significantly higher in the oral group. CONCLUSIONS: When E₂ concentrations are titrated to the normal range, the route of delivery of 17β-E₂ does not affect differentially body composition, lipid oxidation, and lipid concentrations in hypogonadal girls with TS. However, total estrogen exposure (E₁, E₁S, and total bioestrogen) is significantly higher after oral 17β-E₂. TD 17β-E₂ results in a more physiological estrogen milieu than oral 17β-E₂ administration in girls with TS.
Authors: Gary M Leong; Sofia Moverare; Jesena Brce; Nathan Doyle; Klara Sjögren; Karin Dahlman-Wright; Jan-Ake Gustafsson; Ken K Y Ho; Claes Ohlsson; Kin-Chuen Leung Journal: Endocrinology Date: 2004-08-19 Impact factor: 4.736
Authors: Richard J Santen; Lawrence Demers; Susan Ohorodnik; J Settlage; Peter Langecker; D Blanchett; Paul E Goss; Shuping Wang Journal: Steroids Date: 2007-05-21 Impact factor: 2.668
Authors: Robert L Rosenfield; Linda A DiMeglio; Nelly Mauras; Judith Ross; Natalie D Shaw; Siri A W Greeley; Morey Haymond; Karen Rubin; Erinn T Rhodes Journal: J Clin Endocrinol Metab Date: 2015-04 Impact factor: 5.958
Authors: Philippe F Backeljauw; Carolyn Bondy; Steven D Chernausek; Joseph T Cernich; David A Cole; Laura P Fasciano; Joan Foodim; Scott Hawley; David S Hong; Rebecca C Knickmeyer; Paul Kruszka; Angela E Lin; Barbara M Lippe; Gary A Lorigan; Cheryl L Maslen; Nelly Mauras; David C Page; Victoria L Pemberton; Siddharth K Prakash; Charmian A Quigley; Kelly C Ranallo; Allan L Reiss; David E Sandberg; Cindy Scurlock; Michael Silberbach Journal: Am J Med Genet A Date: 2015-04-29 Impact factor: 2.802